Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women

Journal of Ovarian Research

Volumn 8, Issue 1, 2015, Pages

  Tian, Yaping ^a   Wang, Chuanxin ^b   Cheng, Liming ^c   Zhang, Aimin ^d   Liu, Wen ^e   Guo, Lin ^f   Ye, Huiming ^g   Huang, Yanchun ^h   Chen, Jing ⁱ   Wen, Xinyu ^a   Xing, Yuelei ^a   Zheng, Guixi ^b   Sun, Ziyong ^c   Li, Huijun ^c   Zhang, Peng ^d   Liu, Wanli ^e   Chen, Ying ^f   Zhang, Zhongying ^g   Xu, Yi ^h   Huo, Yishan ^h   Ou, Qishui ⁱ   more..

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SHANDONG UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^f FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^g ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

^h XINJIANG MEDICAL UNIVERSITY   (China)

ⁱ FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Epithelial ovarian cancer; Human epididymis protein 4; Pelvic masses

Indexed keywords

CA 125 ANTIGEN; ESTRADIOL; HUMAN EPIDIDYMIS PROTEIN 4; PROGESTERONE; PROTEIN; WFDC2 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MENOPAUSE; OVARY CARCINOMA; PELVIS TUMOR; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SMOKING; ADOLESCENT; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHINA; CLINICAL TRIAL; ETHNOLOGY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; NORMAL HUMAN; OVARY TUMOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POSTMENOPAUSE; PREMENOPAUSE; PROSPECTIVE STUDIES; PROTEINS; REFERENCE VALUES; YOUNG ADULT;

EID: 84946552429     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/s13048-015-0201-z     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Chen WQ, Zheng RS, Zhang SW, Li N, Zhao P, Li GL, et al. Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res. 2012;24:171-80.
3. Tomao F, Papa A, Rossi L, Strudel M, Vici P, Lo Russo G, et al. Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. J Exp Clin Cancer Res. 2013;32:48.
4. Lutz AM, Willmann JK, Drescher CW, Ray P, Cochran FV, Urban N, et al. Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology. 2011;259:329-45.
5. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009;6:e1000114.
6. Cornwall GA, von Horsten HH, Swartz D, Johnson S, Chau K, Whelly S. Extracellular quality control in the epididymis. Asian J Androl. 2007;9:500-7.
7. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695-700.
8. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999;238:375-85.
9. Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013;167:81-5.
10. Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013;66:273-81.
11. Speeckaert MM, Speeckaert R, Delanghe JR. Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker. Adv Clin Chem. 2013;59:1-21.
12. Richards A, Herbst U, Manalang J, Pather S, Saidi S, Tejada-Berges T, et al. HE4, CA125, the risk of malignancy algorithm and the risk of malignancy index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population. Aust N Z J Obstet Gynaecol. 2015;55:493-7.
13. Tang Z, Chang X, Ye X, Li Y, Cheng H, Cui H. Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma. Chin J Cancer Res. 2015;27:309-17.
14. Ferraro S, Schiumarini D, Panteghini M. Human epididymis protein 4: factors of variation. Clin Chim Acta. 2015;438:171-7.
15. Moore RG, Miller MC, Eklund EE, Lu KH, Bast Jr RC, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012;206:349 e1-7.
16. Macedo AC, da Rosa MI, Lumertz S, Medeiros LR. Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis. Int J Gynecol Cancer. 2014;24:1222-31.
17. Mokhtar N, Thevarajah M, Ma N, Mu I. Human epididymis protein 4 reference intervals in a multiethnic asian women population. Asian Pac J Cancer Prev. 2012;13:6391-5.
18. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40-6.
19. Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107:1075-85.
20. Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol. 2013;128:233-8.
21. Azzam AZ, Hashad DI, Kamel NA. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward? Arch Gynecol Obstet. 2013;288:167-72.
22. Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012;33:2117-23.
23. Manganaro L, Michienzi S, Vinci V, Falzarano R, Saldari M, Granato T, et al. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. Oncol Rep. 2013;30:2481-7.
24. Ghezzi F, Cromi A, Siesto G, Serati M, Zaffaroni E, Bolis P. Laparoscopy staging of early ovarian cancer: our experience and review of the literature. Int J Gynecol Cancer. 2009;19 Suppl 2:S7-13.
25. Ghezzi F, Cromi A, Uccella S, Bergamini V, Tomera S, Franchi M, et al. Laparoscopy versus laparotomy for the surgical management of apparent early stage ovarian cancer. Gynecol Oncol. 2007;105:409-13.
26. Bae J, Choi JS, Lee WM, Koh AR, Jung US, Ko JH, et al. Feasibility and efficacy of laparoscopic restaging surgery for women with unexpected ovarian malignancy. Eur J Obstet Gynecol Reprod Biol. 2015;193:46-50.
27. Bogani G, Cromi A, Serati M, Di Naro E, Casarin J, Pinelli C, et al. Laparoscopic and open abdominal staging for early-stage ovarian cancer: our experience, systematic review, and meta-analysis of comparative studies. Int J Gynecol Cancer. 2014;24:1241-9.
28. Braga F, Ferraro S, Mozzi R, Panteghini M. The importance of individual biology in the clinical use of serum biomarkers for ovarian cancer. Clin Chem Lab Med. 2014;52:1625-31.
29. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402-8.
30. Zhen S, Bian LH, Chang LL, Gao X. Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis. Mol Clin Oncol. 2014;2:559-66.
31. Wilailak S, Chan KK, Chen CA, Nam JH, Ochiai K, Aw TC, et al. Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. J Gynecol Oncol. 2015;26:46-53.